156 related articles for article (PubMed ID: 31296233)
1. Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era.
Suarez A; Reilly C; Fajgenbaum DC
Orphanet J Rare Dis; 2019 Jul; 14(1):173. PubMed ID: 31296233
[TBL] [Abstract][Full Text] [Related]
2. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
[TBL] [Abstract][Full Text] [Related]
3. Overview of Castleman disease.
Dispenzieri A; Fajgenbaum DC
Blood; 2020 Apr; 135(16):1353-1364. PubMed ID: 32106302
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas.
Nagy A; Bhaduri A; Shahmarvand N; Shahryari J; Zehnder JL; Warnke RA; Mughal T; Ali S; Ohgami RS
Blood Adv; 2018 Mar; 2(5):481-491. PubMed ID: 29496669
[TBL] [Abstract][Full Text] [Related]
5. Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease.
Nabel CS; Sameroff S; Shilling D; Alapat D; Ruth JR; Kawano M; Sato Y; Stone K; Spetalen S; Valdivieso F; Feldman MD; Chadburn A; Fosså A; van Rhee F; Lipkin WI; Fajgenbaum DC
PLoS One; 2019; 14(6):e0218660. PubMed ID: 31242229
[TBL] [Abstract][Full Text] [Related]
6. T-Cells Subsets in Castleman Disease: Analysis of 28 Cases Including Unicentric, Multicentric and HHV8-Related Clinical Forms.
Fraticelli S; Lucioni M; Neri G; Marchiori D; Cristinelli C; Merli M; Monaco R; Borra T; Lazzaro A; Uccella S; Arcaini L; Paulli M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175521
[TBL] [Abstract][Full Text] [Related]
7. Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.
Sopfe J; Endres A; Campbell K; Hayes K; Trout AT; Liang X; Lorsbach R; O'Brien MM; Cost CR
Pediatr Blood Cancer; 2019 May; 66(5):e27613. PubMed ID: 30680887
[TBL] [Abstract][Full Text] [Related]
8. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M; Wong R; Wu D; Maillard I; Brandstadter J; Munshi N; Bowne W; Elenitoba-Johnson KS; Fössa A; Lechowicz MJ; Chandrakasan S; Pierson SK; Greenway A; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Chadburn A; Fajgenbaum DC
Blood Adv; 2020 Dec; 4(23):6039-6050. PubMed ID: 33284946
[TBL] [Abstract][Full Text] [Related]
9. Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.
Newman SK; Jayanthan RK; Mitchell GW; Carreras Tartak JA; Croglio MP; Suarez A; Liu AY; Razzo BM; Oyeniran E; Ruth JR; Fajgenbaum DC
Yale J Biol Med; 2015 Dec; 88(4):383-8. PubMed ID: 26604862
[TBL] [Abstract][Full Text] [Related]
10. The application of a multidisciplinary approach in the diagnosis of Castleman disease and Castleman-like lymphadenopathies: A 20-year retrospective analysis of clinical and pathological features.
Pelliccia S; Rogges E; Cardoni A; Lopez G; Conte E; Faccini AL; De Vito R; Girardi K; Bianchi A; Annibali O; Fratoni S; Remotti D; De Angelis G; Giordano C; Palumbo G; Scarpino S; Del Porto F; Bianchi MP; Di Gregorio F; Tafuri A; Di Napoli A
Br J Haematol; 2024 Feb; 204(2):534-547. PubMed ID: 37953489
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review.
Fayand A; Boutboul D; Galicier L; Kahn JE; Buob D; Boffa JJ; Cez A; Oksenhendler E; Grateau G; Ducharme-Bénard S; Georgin-Lavialle S
Amyloid; 2019 Dec; 26(4):197-202. PubMed ID: 31364863
[No Abstract] [Full Text] [Related]
12. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. The French paediatric cohort of Castleman disease: a retrospective report of 23 patients.
Borocco C; Ballot-Schmit C; Ackermann O; Aladjidi N; Delaleu J; Giacobbi-Milet V; Jannier S; Jeziorski E; Maurier F; Perel Y; Piguet C; Oksenhendler E; Koné-Paut I; Galeotti C
Orphanet J Rare Dis; 2020 Apr; 15(1):95. PubMed ID: 32303241
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of 65 patients with Castleman disease in a single center in China.
Wang XQ; Zhong NN; Sun Q; Yan SC; Xu GC; Wang YG; Peng LW; Liu B; Bu LL
Sci Rep; 2022 May; 12(1):8694. PubMed ID: 35610300
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Castleman Disease.
Hoffmann C; Hentrich M; Tiemann M; Rosenwald A; Weber F; Willenbacher W; Hübel K
Oncol Res Treat; 2022; 45(11):693-704. PubMed ID: 36219975
[TBL] [Abstract][Full Text] [Related]
18. Castleman Disease: A Multicenter Case Series from Turkey.
Gündüz E; Kırkızlar HO; Ümit EG; Karaman Gülsaran S; Özkocaman V; Özkalemkaş F; Candar Ö; Elverdi T; Küçükyurt S; Paydaş S; Çeneli Ö; Karakuş S; Maral S; Ekinci Ö; İpek Y; Kis C; Güven ZT; Akdeniz A; Celkan T; Eroğlu Küçükdiler AH; Akgün Çağlıyan G; Özçelik Şengöz C; Karataş A; Bulduk T; Özcan A; Belen Apak FB; Canbolat A; Kartal İ; Ören H; Töret E; Özdemir GN; Bakanay Öztürk ŞM
Turk J Haematol; 2022 Jun; 39(2):130-135. PubMed ID: 35176839
[TBL] [Abstract][Full Text] [Related]
19. Use of a claims database to characterize and estimate the incidence rate for Castleman disease.
Munshi N; Mehra M; van de Velde H; Desai A; Potluri R; Vermeulen J
Leuk Lymphoma; 2015 May; 56(5):1252-60. PubMed ID: 25120049
[TBL] [Abstract][Full Text] [Related]
20. TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.
Srkalovic G; Marijanovic I; Srkalovic MB; Fajgenbaum DC
Bosn J Basic Med Sci; 2017 May; 17(2):81-84. PubMed ID: 28135567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
